DLL3-Targeting Antibody Conjugates for Precise Tumor Payload Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for high-grade neuroendocrine tumors such as small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) have poor prognosis and limited therapeutic options, with DLL3 being selectively expressed on tumor cells but not in normal tissues, offering a target for targeted therapy.
Innovation Solution
Development of immunoglobulin-related compositions, including antibodies and antigen binding fragments, that specifically bind to DLL3, internalize on tumor cells, and can be conjugated with therapeutic agents to deliver toxic payloads or serve as diagnostic tools, utilizing recombinant nucleic acid sequences and host cells to produce these compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for high-grade neuroendocrine tumors, then treatment options are available, but prognosis remains poor and therapeutic options are limited
Solution Approach 1:
The patent segments the therapeutic approach by targeting a specific marker (DLL3) expressed on tumor cells but not in normal tissues, allowing for precise differentiation between cancerous and healthy cells. This segmentation enables the development of targeted therapies that act specifically on the tumor without affecting normal tissues, thereby improving prognosis while maintaining therapeutic options through molecular-level precision rather than broad conventional treatments.
Solution Approach 2:
The patent uses DLL3 as an intermediary target - a protein marker that mediates the interaction between therapeutic agents and tumor cells. By conjugating therapeutic agents to antibodies that recognize DLL3, the patent creates a targeted delivery system where the DLL3 marker serves as the intermediary that directs the therapeutic payload specifically to tumor cells, improving treatment efficacy without the need for broad conventional chemotherapy.
2Reliability
If targeted therapy is developed using DLL3 as target, then therapeutic specificity is improved, but development complexity increases
Solution Approach 1:
The patent employs DLL3 as a natural intermediary target that simplifies the development process. Since DLL3 is selectively expressed on tumor cells and not in normal tissues, it serves as an inherent marker that guides the development of targeted therapies without requiring complex identification systems. The antibody-DLL3 interaction provides a straightforward mechanism for targeted delivery, reducing development complexity compared to approaches requiring multiple markers or complex cellular targeting mechanisms.
Solution Approach 2:
The patent replaces complex mechanical or multi-step targeting mechanisms with a simpler immunological recognition system. Instead of using complex delivery vehicles or multiple targeting steps, the patent relies on the natural immune recognition mechanism where antibodies bind to DLL3 markers on tumor cells. This substitution of complex mechanical systems with immunological recognition simplifies the overall therapy development while maintaining high therapeutic specificity.
3Object-affected harmful factors
If therapeutic agents are conjugated to antibodies, then toxic payload delivery to tumor cells is achieved, but manufacturing precision requirements increase
Solution Approach 1:
The patent uses DLL3 as an intermediary target that facilitates precise delivery without requiring extremely tight manufacturing tolerances. The antibody-DLL3 binding interaction provides a natural precision mechanism that is less sensitive to manufacturing variations compared to direct cell-to-cell delivery systems. This intermediary approach allows for robust conjugation chemistry while maintaining precise tumor cell targeting through the biological recognition mechanism.
Solution Approach 2:
The patent employs parameter changes in the conjugation process, utilizing controlled chemical reactions with appropriate reagents and conditions to achieve stable antibody-therapeutic conjugates. By optimizing conjugation parameters such as reagent concentration, reaction time, and environmental conditions, the patent achieves sufficient precision in payload delivery without requiring extreme manufacturing precision. The biological target (DLL3) provides an additional layer of precision that compensates for manufacturing variations.
Data Source
AI summary
The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.